GT Biopharma (GTBP) FCF Margin (2010 - 2015)

GT Biopharma (GTBP) has reported FCF Margin for 5 consecutive years, with 6465.0% the latest figure, recorded in Q2 2015.

• On a quarterly basis, FCF Margin changed N/A year-over-year to 6465.0% in Q2 2015; TTM through Mar 2016 was 15185.0%, a 1408755.0% decrease from a year earlier, with the FY2015 full-year figure at 17251.85%, down 1437480.0% from the prior year.
• FCF Margin was 6465.0% for Q2 2015 at GT Biopharma, up from 25528.57% in the prior quarter.
• Over five years, FCF Margin peaked at 97.72% in Q4 2012 and troughed at 39300.0% in Q2 2011.
• A 4-year average of 12524.07% and a median of 6465.0% in 2015 frame the typical range for FCF Margin.
• Across the five-year window, FCF Margin plunged 1846500 bps in 2012 and surged 1904318 bps in 2013, its largest moves.
• Over 4 years, FCF Margin stood at 10800.0% in 2011, then surged by 99 bps to 97.72% in 2012, then tumbled by 60 bps to 156.82% in 2013, then tumbled by 4023 bps to 6465.0% in 2015.
• The last three FCF Margin figures came in at 6465.0% (Q2 2015), 25528.57% (Q1 2015), and 156.82% (Q1 2013), per Business Quant data.